Crohn's disease is a chronic gastrointestinal inflammatory disorder, characterized by episodes of relapsing and remitting flares. As the disease mechanism becomes better elucidated, there is a significant increase in the number of available biologic therapies. This article summarizes and synthesizes current Food and Drug Administration-approved biological therapy for Crohn's disease and examines the positioning of medical therapy as emerging biologics break onto the market.
CITATION STYLE
Dunleavy, K. A., & Pardi, D. S. (2022). Biologics: How far can they go in Crohn’s disease? Gastroenterology Report. Oxford University Press. https://doi.org/10.1093/gastro/goac049
Mendeley helps you to discover research relevant for your work.